TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest.
Cremolini C, et al. Among authors: masi g.
BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.
BMC Cancer. 2017.
PMID: 28599628
Free PMC article.
Clinical Trial.